About this trial

This study will aim to test whether specific neural circuitry changes, proposed on the basis of a neurocognitive model of anxiety, are a mechanism of action for Cognitive Behavioural Therapy (CBT) interventions. This study aims to provide a theoretical model of the neurobiological mechanisms of CBT's therapeutic effect, where there currently is none, and potentially allow for more targeted/specific approaches to anxiety disorders following the identification of key CBT mechanisms. The ultimate aim is to improve the efficacy of CBT, and more generally, psychological interventions for anxiety disorders.

Eligibility criteria

Qualifiers

Enrolled in IAPT Step 3 (high intensity service)

Score of or above 8 on the GAD-7 (indicating moderate anxiety on a standard scale of anxiety; Spitzer et al., 2006)

Willing and able to provide written consent

Disqualifiers

Score above 22 on the GAD-7

Past/present psychotic disorder, bipolar disorder/mania or alcohol/substance use disorder (outside a comorbid psychiatric episode)

History of medical illness that may impair cognitive function (e.g. serious head injury, endocrine disorder)

Current psychotropic pharmacological intervention (e.g. SSRIs) or use within 3 months

Trial design

Treatments tested in this trial

  • Cognitive Behavioural Therapy
  • Waiting List

Treatment groups

174 Participants
are divided into 2 treatment groups

Locations

1
Institute of Cognitive Neuroscience, University College LondonWC1N 3AZ, London United Kingdom

Sponsors and collaborators

UCLH/UCL Joint Research Office

Lead sponsor

Medical Research Council

Collaborator

Camden and Islington NHS Trust

Collaborator

Central and North West London NHS Foundation Trust

Collaborator